WO2004060384A3 - Pharmaceutical botulinum toxin compositions - Google Patents

Pharmaceutical botulinum toxin compositions Download PDF

Info

Publication number
WO2004060384A3
WO2004060384A3 PCT/IB2003/006145 IB0306145W WO2004060384A3 WO 2004060384 A3 WO2004060384 A3 WO 2004060384A3 IB 0306145 W IB0306145 W IB 0306145W WO 2004060384 A3 WO2004060384 A3 WO 2004060384A3
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum toxin
present
sequestration
compositions
tissues
Prior art date
Application number
PCT/IB2003/006145
Other languages
French (fr)
Other versions
WO2004060384A2 (en
Inventor
Gary E Borodic
Original Assignee
Botulinum Toxin Res Ass Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004060384(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ540425A priority Critical patent/NZ540425A/en
Priority to EP03814518A priority patent/EP1594523B1/en
Priority to AU2003300666A priority patent/AU2003300666A1/en
Priority to CA2510058A priority patent/CA2510058C/en
Priority to MXPA05006690A priority patent/MXPA05006690A/en
Application filed by Botulinum Toxin Res Ass Inc filed Critical Botulinum Toxin Res Ass Inc
Priority to DE60326887T priority patent/DE60326887D1/en
Priority to BR0316871-9A priority patent/BR0316871A/en
Priority to JP2004564369A priority patent/JP2006519761A/en
Publication of WO2004060384A2 publication Critical patent/WO2004060384A2/en
Publication of WO2004060384A3 publication Critical patent/WO2004060384A3/en
Priority to IL168745A priority patent/IL168745A0/en
Priority to NO20053424A priority patent/NO20053424L/en
Priority to AU2010202062A priority patent/AU2010202062A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and delivery of the botulinum toxin to neural and associated tissues, as compared with available formulations of botulinum toxins, and thereby produce a beneficial clinical effect. The sequestration agents of the present invention include proteins, lipids and carbohydrates. A preferred composition of the present invention comprises a botulinum toxin and an albumin. The present invention also provides methods of treating neuromuscular diseases and pain using the disclosed compositions and methods of making the disclosed compositions.
PCT/IB2003/006145 2002-12-20 2003-12-22 Pharmaceutical botulinum toxin compositions WO2004060384A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2004564369A JP2006519761A (en) 2002-12-20 2003-12-22 Improved pharmaceutical botulinum toxin composition
BR0316871-9A BR0316871A (en) 2002-12-20 2003-12-22 Botulically improved toxin pharmaceutical compositions
AU2003300666A AU2003300666A1 (en) 2002-12-20 2003-12-22 Pharmaceutical botulinum toxin compositions
CA2510058A CA2510058C (en) 2002-12-20 2003-12-22 Improved pharmaceutical botulinum toxin compositions
MXPA05006690A MXPA05006690A (en) 2002-12-20 2003-12-22 Pharmaceutical botulinum toxin compositions.
NZ540425A NZ540425A (en) 2002-12-20 2003-12-22 Pharmaceutical botulinum toxin compositions
DE60326887T DE60326887D1 (en) 2002-12-20 2003-12-22 PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM TOXIN AND HUMAN SERUM ALBUMIN
EP03814518A EP1594523B1 (en) 2002-12-20 2003-12-22 Pharmaceutical compositions comprising botulinum toxin and human serum albumin
IL168745A IL168745A0 (en) 2002-12-20 2005-05-23 Compositions comprising botulinum toxin and a human serum albumin, method for producing the same and use thereof in the preparation of medicaments
NO20053424A NO20053424L (en) 2002-12-20 2005-07-14 Improved pharmaceutical botulinum toxin preparations.
AU2010202062A AU2010202062A1 (en) 2002-12-20 2010-05-20 Pharmaceutical botulinum toxin compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43590102P 2002-12-20 2002-12-20
US60/435,901 2002-12-20

Publications (2)

Publication Number Publication Date
WO2004060384A2 WO2004060384A2 (en) 2004-07-22
WO2004060384A3 true WO2004060384A3 (en) 2004-10-07

Family

ID=32713047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/006145 WO2004060384A2 (en) 2002-12-20 2003-12-22 Pharmaceutical botulinum toxin compositions

Country Status (17)

Country Link
US (2) US7491403B2 (en)
EP (1) EP1594523B1 (en)
JP (1) JP2006519761A (en)
KR (1) KR20050094817A (en)
CN (1) CN100525831C (en)
AT (1) ATE426408T1 (en)
AU (2) AU2003300666A1 (en)
BR (1) BR0316871A (en)
CA (1) CA2510058C (en)
CR (1) CR9813A (en)
DE (1) DE60326887D1 (en)
IL (1) IL168745A0 (en)
MX (1) MXPA05006690A (en)
NO (1) NO20053424L (en)
NZ (1) NZ540425A (en)
WO (1) WO2004060384A2 (en)
ZA (1) ZA200504982B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
WO2004060384A2 (en) * 2002-12-20 2004-07-22 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
ES2338017T3 (en) * 2004-01-05 2010-05-03 Botulinum Toxin Research Associates, Inc. METHODS OF USE OF BOTULINIC TOXIN FOR THE TREATMENT OF DEFORMATION OF HYPERVOLEMIC LIPS (ECTROPION OF LIPS).
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR100852824B1 (en) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 Therapeutic composition with a botulinum neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
AU2013202882B2 (en) * 2005-08-01 2015-11-19 Allergan, Inc Improved botulinum toxin compositions
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
PT3144013T (en) 2005-12-01 2019-02-07 Univ Massachusetts Lowell Botulinum nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20080063732A1 (en) * 2006-07-31 2008-03-13 Hantash Basil M Method of increasing the efficacy of neurotoxin
CA2671133C (en) 2006-12-01 2015-11-24 Anterios, Inc. Peptide nanoparticles and uses therefor
US20100150994A1 (en) 2006-12-01 2010-06-17 Anterios, Inc. Amphiphilic entity nanoparticles
CN101765423B (en) 2007-05-31 2014-08-06 安特里奥公司 Nucleic acid nanoparticles and uses therefor
KR100882817B1 (en) * 2007-07-20 2009-02-10 숙명여자대학교산학협력단 Pharmaceutical composition for improving engraftment of adipose cell comprising botulinum toxin as an active ingredient
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009137819A1 (en) 2008-05-09 2009-11-12 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
AU2010204445B2 (en) * 2009-01-07 2015-09-03 2405871 Ontario Inc. Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
WO2011005577A1 (en) * 2009-06-24 2011-01-13 Soparkar Charles N S Zinc supplementation to increase responsiveness to metalloprotease therapy
WO2011056684A2 (en) 2009-10-27 2011-05-12 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
KR101820542B1 (en) 2009-11-11 2018-01-19 호라이라 인코포레이티드 Systems, apparatuses, and methods for treating tissue and controlling stenosis
ES2634669T3 (en) 2011-02-08 2017-09-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan degradation enzyme and use thereof for the treatment of benign prostatic hyperplasia
MX358613B (en) 2012-03-12 2018-08-27 J Binder William Treatment of migraine headaches with presynaptic neurotoxin.
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN108463242A (en) * 2016-03-02 2018-08-28 梅尔兹制药公司 Include the composition of botulin toxin
AU2017236163A1 (en) * 2016-03-25 2018-10-11 Ipsen Biopharm Limited Collecting physical therapy information to enhance treatment efficacy of botulinum toxin
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
KR101636846B1 (en) * 2016-06-08 2016-07-07 (주)넥스젠바이오텍 Botulium toxin-human epidermal growth factor fusion protein with increased skin cell proliferation and antioxidative effect and cosmetic composition for improving wrinkle and promoting skin reproduction comprising the same as effective component
EP3503877B8 (en) * 2016-08-26 2022-04-20 SK Joint Ventures II, LLC Biodegradable polymer formulations for extended efficacy of botulinum toxin
US10369190B2 (en) 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
BR112019010131A2 (en) 2016-11-21 2019-10-08 Eirion Therapeutics Inc transdermal delivery of large agents
CN106860756A (en) * 2017-03-29 2017-06-20 卢仁华 The medicine of blepharospasm
RU2019143639A (en) * 2017-05-31 2021-06-30 Аллерган, Инк. BOTULINIC NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH OVERACTIVE MELANOCYTES AND / OR EXCESS MELANIN
KR20190038292A (en) * 2017-09-29 2019-04-08 한국프라임제약주식회사 A novel botulinum toxin composition having a prolonged period of action
US20210177946A1 (en) * 2018-08-28 2021-06-17 Ira Sanders Therapeutic medications for the sphenopalatine ganglion
WO2024049286A1 (en) * 2022-09-02 2024-03-07 (주)메디톡스 Botulinum toxin formulation having reduced resistance expression, and method related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
WO1997035604A1 (en) * 1996-03-27 1997-10-02 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
WO2001058472A2 (en) * 2000-02-08 2001-08-16 Allergan, Inc. Botulinum toxin pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5069936A (en) 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5034461A (en) 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP0593176A3 (en) * 1992-09-28 1995-03-01 Wisconsin Alumni Res Found Pharmaceutical compositions containing botulinum toxin and method of preparation.
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5401452A (en) 1993-07-26 1995-03-28 Environmental Protection Polymers, Inc. Methods for encapsulating waste and products thereof
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
DE69511860T2 (en) 1994-05-31 2000-02-10 Allergan Inc MODIFICATION OF CLOSTRIDIUM TOXINES AND THEIR USE AS TRANSPORT PROTEINS
US5583162A (en) 1994-06-06 1996-12-10 Biopore Corporation Polymeric microbeads and method of preparation
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1996039166A1 (en) 1995-06-06 1996-12-12 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin
DK0773788T3 (en) * 1995-06-06 2003-09-01 Allergan Inc Improved Preparations and Methods for Chemodevelopment Using Neurotoxins
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
JP2002528421A (en) * 1998-10-27 2002-09-03 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ How to promote wound healing
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (en) * 2001-01-05 2002-07-05 Univ Degli Studi Udine USE OF BOTULIN TOXIN FOR THE SOLUTION OF JOINT PATHOLOGIES, IN PARTICULAR OF COXARTROSIS, EPICONDYLITIS AND PATHOLUS
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
MXPA01011542A (en) * 2001-11-13 2003-05-22 Alcon Inc Regeneration of articular cartilage damaged by osteoarthritis i and ii, by means of intra-articular application of sodium hyaluronate and chondroitin sulphate in a gel carrier.
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
WO2004060384A2 (en) * 2002-12-20 2004-07-22 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions
MXPA05009425A (en) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin.
US7335367B2 (en) * 2003-03-06 2008-02-26 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
ES2338017T3 (en) * 2004-01-05 2010-05-03 Botulinum Toxin Research Associates, Inc. METHODS OF USE OF BOTULINIC TOXIN FOR THE TREATMENT OF DEFORMATION OF HYPERVOLEMIC LIPS (ECTROPION OF LIPS).
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
WO1997035604A1 (en) * 1996-03-27 1997-10-02 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
WO2001058472A2 (en) * 2000-02-08 2001-08-16 Allergan, Inc. Botulinum toxin pharmaceutical compositions

Also Published As

Publication number Publication date
CN100525831C (en) 2009-08-12
WO2004060384A2 (en) 2004-07-22
MXPA05006690A (en) 2006-02-17
EP1594523B1 (en) 2009-03-25
NO20053424L (en) 2005-09-16
BR0316871A (en) 2005-10-18
CN1729011A (en) 2006-02-01
AU2003300666A1 (en) 2004-07-29
ATE426408T1 (en) 2009-04-15
EP1594523A2 (en) 2005-11-16
NZ540425A (en) 2009-03-31
DE60326887D1 (en) 2009-05-07
US20110293663A1 (en) 2011-12-01
ZA200504982B (en) 2007-05-30
KR20050094817A (en) 2005-09-28
JP2006519761A (en) 2006-08-31
AU2010202062A1 (en) 2010-06-10
US20040151741A1 (en) 2004-08-05
US8241640B2 (en) 2012-08-14
NO20053424D0 (en) 2005-07-14
IL168745A0 (en) 2011-12-01
US7491403B2 (en) 2009-02-17
CA2510058C (en) 2010-03-16
CA2510058A1 (en) 2004-07-22
CR9813A (en) 2008-07-29

Similar Documents

Publication Publication Date Title
WO2004060384A3 (en) Pharmaceutical botulinum toxin compositions
AU2019201902B8 (en) Dermal delivery
US20120321579A1 (en) Surfactant compositions
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
JP6131194B2 (en) Empty nanoparticle composition and use thereof for treating dermatological symptoms
WO2006086631A3 (en) Methods for implementing microbeam radiation therapy
KR20140003573A (en) Oil compositions
JP2020511548A (en) Botulinum neurotoxin for treatment
WO2008067049A3 (en) Particles for cell targeting
DE60119976D1 (en) Thixotropes nasenspray
WO1999002120A3 (en) Compositions and methods for reversibly increasing permeability of biomembranes
WO2002080981A3 (en) Polynucleotide binding complexes comprising sterols and saponins
BG105924A (en) Composition for the treatment of psoriasis
Elwood Adapalene advancing on tretinoin in the treatment of acne
MX2013001099A (en) Gel or cream of topical application with botulinum neurotoxin encapsulated in liposomal nanoparticles for treating hyperhidrosis.
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 168745

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 00483/MUMNP/2005

Country of ref document: IN

Ref document number: 483/MUMNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003300666

Country of ref document: AU

Ref document number: 540425

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: CR2005-007863

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2003814518

Country of ref document: EP

Ref document number: 2510058

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057011339

Country of ref document: KR

Ref document number: 2004564369

Country of ref document: JP

Ref document number: 05059213

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2005/04982

Country of ref document: ZA

Ref document number: PA/a/2005/006690

Country of ref document: MX

Ref document number: 200504982

Country of ref document: ZA

Ref document number: 20038A67969

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057011339

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0316871

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 2003814518

Country of ref document: EP